Genetic reduction in ANGPTL3 and ANGPTL4 is associated with lower risk of chronic kidney disease (CKD) via enhanced lipoprotein lipase (LPL) activity, according to results of a drug target Mendelian randomisation (MR) study and single cell RNA sequencing analyses.
